Evidence map›Paper›PMID 36852839›Full record

SynthesisTherapeutic advances in cardiovascular disease

Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study.

Elmira Jafari Afshar, Parham Samimisedeh, Amirhossein Tayebi, Neda Shafiabadi Hassani, Hadith Rastad, Shahrooz Yazdani

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Therapeutic advances in cardiovascular disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Elmira Jafari AfsharCardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Parham SamimisedehCardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran.ORCID 0000-0002-3667-8142
Amirhossein TayebiCardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Neda Shafiabadi HassaniCardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Hadith RastadNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Shahrooz YazdaniAssociate Professor of Interventional Cardiology, Cardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Jahrom University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, no pharmacological or device-based intervention has been fully proven to reverse the no-reflow phenomenon.

objectivesTo assess the efficacy and safety of intracoronary (IC) epinephrine in the management of no-reflow phenomenon following percutaneous coronary intervention (PCI), either as first-line treatment or after the failure of conventional agents.

designSystematic review. DATA SOURCES AND

methodsPubMed and Scopus databases were systematically searched up to 28 May 2022, with additional manual search on the Google Scholar and review of the reference lists of the relevant studies to identify all published studies. Cohort studies, case series, and interventional studies written in English which evaluated the efficacy and safety of IC epinephrine in patients with no-flow phenomenon were included in our review.

resultsSix of the 646 articles identified in the initial search met our inclusion criteria. IC epinephrine was used either as a first-line treatment [two randomized clinical trials (RCTs)] or after the failure of conventional agents (two cohort studies and two case series) for restoring the coronary flow, mainly after primary PCI. As first-line therapy, IC epinephrine successfully restored coronary flow in over 90% of patients in both RCTs, which significantly outperformed IC adenosine (78%) but lagged behind combination of verapamil and tirofiban (100%) in this regard. In the refractory no-flow phenomenon, successful reperfusion [thrombolysis in myocardial infarction (TIMI) flow grade = 3] was achieved in three out of four patients after the administration of IC epinephrine based on the results from both case series. Their findings were confirmed by a recent cohort study that further compared IC epinephrine with IC adenosine and found significant differences between them in terms of efficacy [% TIMI flow grade 3: (69.1%

conclusionResults from available evidence suggest that IC epinephrine might be an effective and safe agent in managing the no-reflow phenomenon.

Indexed as

No-Reflow PhenomenonPercutaneous Coronary InterventionAdenosineEpinephrineHeartHumansAdenosineEpinephrineepinephrineno-reflow phenomenonPCIreperfusion therapyTIMI

Identifiers

PMID36852839
PMCPMC10071100
OpenAlexW4322617203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.